|
|
| (13 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atorvastatin#Warnings]] |
| {{Atorvastatin}}
| |
| {{CMG}} ; {{AE}} , {{PB}}
| |
| | |
| | |
| Skeletal muscle effects (e.g., [[myopathy]] and [[rhabdomyolysis]]): Risks increase when higher doses are used concomitantly with [[cyclosporine]] and strong [[CYP3A4]] inhibitors (e.g., [[clarithromycin]], [[itraconazole]], HIV [[protease inhibitor]]s). Predisposing factors include advanced age (> 65), uncontrolled [[hypothyroidism]], and renal impairment.
| |
| | |
| Rare cases of [[rhabdomyolysis]] with [[acute renal failure]] secondary to [[myoglobinuria]] have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if [[myopathy]] is diagnosed or suspected.
| |
| | |
| Liver enzyme abnormalities: Persistent elevations in hepatic [[transaminase]]s can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.
| |
| | |
| A higher incidence of [[hemorrhagic stroke]] was seen in patients without [[CHD]] but with [[stroke]] or [[TIA]] within the previous 6 months in the LIPITOR 80 mg group vs placebo.
| |